ClinicalTrials.gg
CompletedNCT03496870Updated Mar 22, 2019

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

A Phase 1 interventional study of Opicapone and Carbidopa Levodopa in Parkinson Disease, sponsored by Neurocrine Biosciences. Completed at 3 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-03-22.

Sponsored by Neurocrine Biosciences · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2018, 8 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 38 studies testing opicapone in Parkinson Disease — none open to participants now, none under way, none of them phase 3. opicapone · Parkinson Disease.

Enrollment
29th of 38
16 · median 28
Started
2018
with 1 other
Phase 1
27 of 38
none open now
Registered
30th of 38
by date
Lead sponsor
1 of 38
Neurocrine Biosciences

Among the 38 studies testing opicapone in Parkinson Disease, this one is the 29th largest by enrollment, is one of 2 that started in 2018, is one of 27 in phase 1, and was the 30th registered.

Parkinson Disease

4,581 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 38 studies testing opicapone in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About opicapone

opicapone: first FDA approval 2020 (ONGENTYS), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 38 studies testing opicapone in Parkinson Disease as a file.
02

Study summary

This is a phase 1, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of opicapone when administered orally once daily for 14 days as adjunctive therapy to carbidopa/levodopa in subjects with Parkinson's disease.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a clinical diagnosis of idiopathic Parkinson's Disease (PD) for at least 3 years with clear improvement with levodopa treatment
  2. Be at a stable dose of maintenance medication(s) for PD, including stable doses of CD/LD
  3. Subjects of who do not practice total abstinence must agree to use hormonal or two forms of nonhormonal (dual contraception) consistently during the screening, treatment and follow-up periods of the study
  4. Have a (BMI) of 18 to 40 kg/m2
  5. Have a modified Hoehn and Yahr stage of ≤4 in the OFF state
  6. Be able to tolerate an overnight period of 12 hours without CD/LD
  7. Be in good general health and expected to complete the clinical study as designed

Exclusion criteria

Exclusion Criteria:

  1. Are currently pregnant or breastfeeding
  2. More than 2 alcoholic beverages daily or more than 14 alcoholic beverages weekly within 7 days of Day -1 or consume any alcohol within 48 hours of Day -1.
  3. Have motor fluctuations during the day (ie, effect of levodopa "wearing off" or having unpredictable "off" periods), or severe or intolerable levodopa-induced dyskinesia
  4. Have had previous exposure to opicapone, or have an allergy, , or intolerance to opicapone or other COMT inhibitor.
  5. Have a history of a medical condition or surgical procedure that might interfere with absorption or metabolism.
  6. Have a known history of neuroleptic malignant syndrome
  7. Have an unstable medical condition or chronic disease
  8. Have taken certain prohibited medications within 28 days of Day -1.
  9. Have a known or suspected diagnosis of AIDS, or have tested seropositive for
  10. Have hepatitis A or B
  11. Have a significant risk of suicidal or violent behavior
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Opicapone once daily with Carbidopa/Levodopa

    Opicapone administered once daily for 14 days; carbidopa/levodopa administered at set frequency on Study Days 1, 2 \& 15

    Drug: Opicapone · Drug: Carbidopa Levodopa

Interventions

  • catechol-O-methyltransferase (COMT) inhibitor

    Also known as: BIA 9-1067

  • DrugCarbidopa Levodopa

    Levodopa: dopamine precursor Carbidopa: DOPA decarboxylase inhibitor

    Also known as: Sinemet

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic evaluation of opicapone and its metabolites: area under the curve (AUC 0-24)

    Area under the plasma concentration versus time curve from 0 to 24 hours for analytes with quantifiable concentrations at 24 hours postdose

    Time frame: up to 19 days

  2. Pharmacokinetic evaluation of opicapone and its metabolites: area under the curve (AUC 0-tlast)

    Area under the plasma concentration versus time curve from 0 hour to the time of the last measurable concentration for analytes below the limit of quantification at 24 hours postdose

    Time frame: up to 19 days

  3. Pharmacokinetic evaluation of opicapone and its metabolites: Maximum plasma concentration (Cmax)

    Maximum plasma concentration

    Time frame: up to 19 days

  4. Pharmacokinetic evaluation of opicapone and its metabolites: Time to maximum plasma concentration (tmax)

    Time to maximum plasma concentration

    Time frame: up to 19 days

  5. Pharmacokinetic evaluation of levodopa following administration of opicapone: area under the curve (AUC 0-tlast)

    Area under the plasma concentration versus time curve from 0 hours to time before next levodopa dose

    Time frame: up to 15 days

  6. Pharmacokinetic evaluation of levodopa following administration of opicapone: maximum plasma concentration (cmax)

    Maximum plasma concentration

    Time frame: up to 15 days

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (safety and tolerability)

    Number of participants with reported adverse events after study treatment.

    Time frame: up to 19 days

  2. Pharmacodynamic evaluation of opicapone on S-COMT activity

    Maximum inhibition of S-COMT activity.

    Time frame: up to 19 days

07

Study locations

3 sites
  • Neurocrine Clinical Site
    Glendale, California 91206, United States
  • Neurocrine Clinical Site
    Long Beach, California 90806, United States
  • Neurocrine Clinical Site
    Farmington Hills, Michigan 48334, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Jul 2018, 4 months.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 4 months is below that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2018
First posted
Apr 12, 2018
StartActual
Feb 8, 2018
Primary completionActual
Jul 2, 2018
CompletionActual
Jul 2, 2018
Last update
Mar 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03496870
Responsible party
Sponsor
First posted
Apr 12, 2018
Start date
Feb 8, 2018
Primary completion
Jul 2, 2018
Completion
Jul 2, 2018
Last update
Mar 22, 2019

Study contacts

Chief Medical Officer
study director · Chief Medical Officer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opicapone

Start the discussion